Dimethyl sulfoxide (DMSO): a solvent that may solve selected cutaneous clinical challenges

Karim, Maria; Boikess, Robert S.; Schwartz, Robert A.; Cohen, Philip

doi:10.1007/s00403-022-02494-1

Cited by 12 publications

(8 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our case experienced delayed extravasation without acute signs. At this time, there was no firm recommendation on the management of delayed extravasation 17 and the emergency use of standard antidote such as hyaluronidase will not have any positive effect. 2 Given that there is no evidence of an inflammatory process in extravasation, the use of intradermal or systemic glucocorticoids is not recommended and can worsen tissue destruction and increase the need for surgical interventions, especially in the case of vinca alkaloids and epipodophyllotoxins.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…In addition to the mentioned effects, the positive effects of DMSO on revitalizing the skin and healing injuries have been reported. 17,20,23 According to studies DMSO has been effective in off-label treatment of anthracyclines and mitomycin extravasation. 18,24,25 In a case report, extravasation occurred during the infusion of doxorubicin and vincristine, which was immediately treated with chondroitin sulfate subcutaneously, and DMSO solution was used topically for 2 weeks, which finally resolved all inflammatory effects.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, the administration of hyaluronidase as an antidote in an infected area is not advised due to the risk of spreading the infection. 17 Betamethasone topical cream every 6 h and dimethyl sulfoxide (DMSO) every 6 h was started on the second day of hospitalization. The use of DMSO was separated by at least three hours from the topical betamethasone cream.…”

Section: Management and Outcomementioning

confidence: 99%

See 3 more Smart Citations

Delayed presentation of vincristine extravasation

Ghaffary

Gholami

Samankan

et al. 2023

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Vincristine is a vesicant chemotherapeutic agent which may leak from the vessel at the infusion site to the perivascular tissue and cause extravasation. Extravasation, a severe complication of chemotherapeutic drugs, can result in tissue necrosis that is considered an oncological emergency. Case report We aimed to report a case of a 29-year-old woman with ALL-B cell (Acute lymphoblastic leukemia) on maintenance chemotherapy regimen including vincristine, methotrexate, prednisolone, and 6-mercaptopurine (POMP). 48 h after administering intravenous vincristine, the patient experienced burning, pain and tenderness at the injection site (left hand – cubital cavity). Management & outcome 7 days after the onset of symptoms, the patient was hospitalized with a large brown lesion at the site. She was prescribed betamethasone cream, DSMO (Dimethyl sulfoxide) solution, and oral levofloxacin on his second day after admission. The lesion was completely improved 10 days after initiation of therapy and there were no serious problems. Discussion Due to the ineffectiveness of antidote therapy for the management of delayed extravasation of vincristine and beneficial effect of our clinical approach, it could consider for the management of similar cases with delayed extravasation following vincristine administration.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Management and Outcomementioning

confidence: 99%

See 2 more Smart Citations

Delayed presentation of vincristine extravasation

Ghaffary

Gholami

Samankan

et al. 2023

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…DMSO is used in animals and humans through various routes, including dermal and oral, and it is also utilized to enhance the absorption of many other chemicals along these same routes. At low concentrations, DMSO exhibits anti-inflammatory, analgesic, diuretic, vasodilator, anti-platelet aggregation, radio-protective, and muscle-relaxing properties [ 1 ]. The observed beneficial effects on skin rejuvenation and recovery from thermal injury might be explained by its effective property of being a vigorous scavenger of hydroxyl free radicals.…”

Section: Introductionmentioning

confidence: 99%

Monitoring Distribution of the Therapeutic Agent Dimethyl Sulfoxide via Solvatochromic Shift of Albumin-Bound Indocyanine Green

Cho,

Nouizi,

Kim

et al. 2023

Sensors

View full text Add to dashboard Cite

We recently developed a novel hyperspectral excitation-resolved near-infrared fluorescence imaging system (HER-NIRF) based on a continuous-wave wavelength-swept laser. In this study, this technique is applied to measure the distribution of the therapeutic agent dimethyl sulfoxide (DMSO) by utilizing solvatochromic shift in the spectral profile of albumin-bound Indocyanine green (ICG). Using wide-field imaging in turbid media, complex dynamics of albumin-bound ICG are measured in mixtures of dimethyl sulfoxide (DMSO) and water. Phantom experiments are conducted to evaluate the performance of the HER-NIRF system. The results show that the distribution of DMSO can be visualized in the wide-field reflection geometry. One of the main purposes of the DMSO is to act as a carrier for other drugs, enhancing their effects by facilitating skin penetration. Understanding the solubility and permeability of drugs in vivo is very important in drug discovery and development. Hence, this HER-NIRF technique has great potential to advance the utilization of the therapeutic agent DMSO by mapping its distribution via the solvatochromic shift of ICG. By customizing the operational wavelength range, this system can be applied to any other fluorophores in the near-infrared region and utilized for a wide variety of drug delivery studies.

show abstract

Synergistic effect of antibiotics, α-linolenic acid and solvent type against Staphylococcus aureus biofilm formation

Knap,

Kwiecień,

Ochońska

et al. 2024

Pharmacol. Rep

View full text Add to dashboard Cite

Background A promising approach to the treatment of bacterial infections involves inhibiting the quorum sensing (QS) mechanism to prevent the formation and growth of bacterial biofilm. While antibiotics are used to kill remaining bacteria, QS inhibitors (QSIs) allow for antibiotic doses to be reduced. This study focuses on evaluating the synergy between gentamicin sulphate (GEN), tobramycin (TOB), or azithromycin (AZM) with linolenic acid (LNA) against the formation of an early Staphylococcus aureus biofilm. Methods Minimum biofilm inhibitory concentration (MBIC) was determined using the resazurin reduction assay for all antibiotics and LNA. The reduction of biofilm mass was assessed using the crystal violet (CV) assay. We have also evaluated the effect of dimethyl sulfoxide with TWEEN (DMSO_T) on early biofilm formation. Synergy was determined by metabolic activity assay and fractional biofilm inhibitory concentration (FBIC). Results DMSO_T at a concentration of 1% enhanced early biofilm formation, but also decreased the doses of antibiotic needed to reduce the biofilm by up to 8 times. Adding LNA at a concentration of 32 µg/ml or 64 µg/ml allowed up to a 32-fold reduction of antibiotic doses for GEN and TOB and a 4-fold reduction for AZM. Conclusions LNA’s use in combination with various antibiotics could reduce their doses and help fight drug-resistant bacteria in the biofilm.

show abstract

Dimethyl sulfoxide (DMSO): a solvent that may solve selected cutaneous clinical challenges

Cited by 12 publications

References 43 publications

Delayed presentation of vincristine extravasation

Delayed presentation of vincristine extravasation

Monitoring Distribution of the Therapeutic Agent Dimethyl Sulfoxide via Solvatochromic Shift of Albumin-Bound Indocyanine Green

Synergistic effect of antibiotics, α-linolenic acid and solvent type against Staphylococcus aureus biofilm formation

Contact Info

Product

Resources

About